

**DRAFT
TOXICOLOGICAL PROFILE FOR
AMERICIUM**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry**

July 2001

DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

UPDATE STATEMENT

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology/Toxicology Information Branch
1600 Clifton Road NE, E-29
Atlanta, Georgia 30333

FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public. We plan to revise these documents in response to public comments and as additional data become available. Therefore, we encourage comments that will make the toxicological profile series of the greatest use.

Comments should be sent to:

Agency for Toxic Substances and Disease Registry
Division of Toxicology
1600 Clifton Road, N.E.
Mail Stop E-29
Atlanta, Georgia 30333

Background Information

The toxicological profiles are developed by ATSDR pursuant to Section 104(i) (3) and (5) of the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund) for hazardous substances found at Department of Energy (DOE) waste sites. CERCLA directs ATSDR to prepare toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. ATSDR and DOE entered into a Memorandum of Understanding on November 4, 1992 which provided that ATSDR would prepare toxicological profiles for hazardous substances based upon ATSDR's or DOE's identification of need. The current ATSDR priority list of hazardous substances at DOE NPL sites was announced in the Federal Register on July 24, 1996 (61 FR 38451).

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and is being made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Jeffrey P. Koplan, M.D., M.P.H.
Administrator
Agency for Toxic Substances and
Disease Registry

QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance's relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, and assesses the significance of toxicity data to human health.

Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by *type of health effect* (death, systemic, immunologic, reproductive), by *route of exposure*, and by *length of exposure* (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

Pediatrics: Four new sections have been added to each Toxicological Profile to address child health issues:

Section 1.7	How Can (Chemical X) Affect Children?
Section 1.8	How Can Families Reduce the Risk of Exposure to (Chemical X)?
Section 3.7	Children's Susceptibility
Section 6.6	Exposures of Children

Other Sections of Interest:

Section 3.8	Biomarkers of Exposure and Effect
Section 3.11	Methods for Reducing Toxic Effects

ATSDR Information Center

Phone: 1-888-42-ATSDR or (404) 498-0110 **Fax:** (404) 498-0057
E-mail: atsdric@cdc.gov **Internet:** <http://www.atsdr.cdc.gov>

The following additional material can be ordered through the ATSDR Information Center:

Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure history is provided. Other case studies of interest include *Reproductive and Developmental Hazards*; *Skin Lesions and Environmental Exposures*; *Cholinesterase-Inhibiting Pesticide Toxicity*; and numerous chemical-specific case studies.

Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. *Contact:* NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. *Contact:* NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. *Contact:* NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

Radiation Emergency Assistance Center/Training Site (REAC/TS) provides support to the U.S. Department of Energy, the World Health Organization, and the International Atomic Energy Agency in the medical management of radiation accidents. A 24-hour emergency response program at the Oak Ridge Institute for Science and Education (ORISE), REAC/TS trains, consults, or assists in the response to all kinds of radiation accidents. *Contact:* Oak Ridge Institute for Science and Education, REAC/TS, PO Box 117, MS 39, Oak Ridge, TN 37831-0117 • Phone 865-576-3131 • FAX 865-576-9522 • 24-Hour Emergency Phone 865-576-1005 (ask for REAC/TS) • e-mail: cooleyp@ornl.gov • website (including emergency medical guidance): <http://www.ornl.gov/reacts/default.htm>

Referrals

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. *Contact:* AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: aoec@dgs.dgssys.com • AOEC Clinic Director: <http://occ-env-med.mc.duke.edu/oem/aoec.htm>.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. *Contact:* ACOEM, 55 West Seegers Road, Arlington Heights, IL 60005 • Phone: 847-818-1800 • FAX: 847-818-9266.

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHORS(S):

Sam Keith, M.S., C.H.P
ATSDR, Division of Toxicology, Atlanta, GA

David W. Wohlers, Ph.D
Gloria W. Sage, Ph.D.
Gary L. Diamond, Ph.D.
Michael Neal, Ph.D.
Syracuse Research Corporation, North Syracuse, NY

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Research Implementation Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.

PEER REVIEW

A peer review panel was assembled for americium. The panel consisted of the following members:

1. Raymond Guilmette, Ph.D., Manager, Radiation Toxicology Program, Lovelace Respiratory Research Institute, Albuquerque, NM
2. Ronald Kathren, C.H.P., D.E.E., Professor of Pharmaceutical Science, Washington State University; President, The Kathren Group, Inc., Richland, WA
3. Raymond Lloyd, Ph.D., Professor Emeritus of Radiobiology, University of Utah School of Medicine, Taylorsville, UT
4. Melvin Sikov, Ph.D., Scientist Emeritus, Pacific Northwest National Laboratory, Richland, WA

These experts collectively have knowledge of americium's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

CONTENTS

FOREWORD	v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS	vii
CONTRIBUTORS	xi
PEER REVIEW	xiii
LIST OF FIGURES	xix
LIST OF TABLES	xxi
1. PUBLIC HEALTH STATEMENT	1
1.1 WHAT IS AMERICIUM?	1
1.2 WHAT HAPPENS TO AMERICIUM WHEN IT ENTERS THE ENVIRONMENT?	4
1.3 HOW MIGHT I BE EXPOSED TO AMERICIUM?	5
1.4 HOW CAN AMERICIUM ENTER AND LEAVE MY BODY?	6
1.5 HOW CAN AMERICIUM AFFECT MY HEALTH?	6
1.6 HOW CAN AMERICIUM AFFECT CHILDREN?	7
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO AMERICIUM?	8
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO AMERICIUM?	8
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?	9
1.10 WHERE CAN I GET MORE INFORMATION?	10
2. RELEVANCE TO PUBLIC HEALTH	11
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO AMERICIUM IN THE UNITED STATES	11
2.2 SUMMARY OF HEALTH EFFECTS	12
2.3 MINIMAL RISK LEVELS	14
3. HEALTH EFFECTS	15
3.1 INTRODUCTION	15
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE	15
3.2.1 Inhalation Exposure	17
3.2.1.1 Death	17
3.2.1.2 Systemic Effects	18
3.2.1.3 Immunological and Lymphoreticular Effects	21
3.2.1.4 Neurological Effects	22
3.2.1.5 Reproductive Effects	22
3.2.1.6 Developmental Effects	22
3.2.1.7 Cancer	22
3.2.2 Oral Exposure	22
3.2.2.1 Death	22
3.2.2.2 Systemic Effects	22
3.2.2.3 Immunological and Lymphoreticular Effects	22

3.2.2.4	Neurological Effects	22
3.2.2.5	Reproductive Effects	22
3.2.2.6	Developmental Effects	22
3.2.2.7	Cancer	22
3.2.3	Dermal Exposure	23
3.2.3.1	Death	23
3.2.3.2	Systemic Effects	23
3.2.3.3	Immunological and Lymphoreticular Effects	24
3.2.3.4	Neurological Effects	24
3.2.3.5	Reproductive Effects	24
3.2.3.6	Developmental Effects	24
3.2.3.7	Cancer	24
3.2.4	External Exposure	24
3.2.4.1	Death	25
3.2.4.2	Systemic Effects	25
3.2.4.3	Immunological and Lymphoreticular Effects	25
3.2.4.4	Neurological Effects	25
3.2.4.5	Reproductive Effects	25
3.2.4.6	Developmental Effects	25
3.2.4.7	Cancer	25
3.2.5	Other Routes of Exposure	25
3.2.5.1	Death	25
3.2.5.2	Systemic Effects	25
3.2.5.3	Immunological and Lymphoreticular Effects	26
3.2.5.4	Neurological Effects	26
3.2.5.5	Reproductive Effects	27
3.2.5.6	Developmental Effects	27
3.2.5.7	Cancer	27
3.3	GENOTOXICITY	28
3.4	TOXICOKINETICS	29
3.4.1	Absorption	29
3.4.1.1	Inhalation Exposure	29
3.4.1.2	Oral Exposure	34
3.4.1.3	Dermal Exposure	40
3.4.1.4	Other Routes of Exposure	40
3.4.2	Distribution	40
3.4.2.1	Inhalation Exposure	40
3.4.2.2	Oral Exposure	45
3.4.2.3	Dermal Exposure	45
3.4.2.4	Other Routes of Exposure	46
3.4.3	Metabolism	47
3.4.3.1	Inhalation Exposure	47
3.4.3.2	Oral Exposure	47
3.4.3.3	Dermal Exposure	47
3.4.4	Elimination and Excretion	47
3.4.4.1	Inhalation Exposure	47
3.4.4.2	Oral Exposure	49
3.4.4.3	Dermal Exposure	50
3.4.4.4	Other Routes of Exposure	50
3.4.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	51

3.5	MECHANISMS OF ACTION	77
3.5.1	Pharmacokinetic Mechanisms	77
3.5.2	Mechanisms of Toxicity	80
3.5.3	Animal-to-Human Extrapolations	80
3.6	ENDOCRINE DISRUPTION	81
3.7	CHILDREN'S SUSCEPTIBILITY	81
3.8	BIOMARKERS OF EXPOSURE AND EFFECT	85
3.8.1	Biomarkers Used to Identify or Quantify Exposure to Americium	86
3.8.2	Biomarkers Used to Characterize Effects Caused by Americium	86
3.9	INTERACTIONS WITH OTHER CHEMICALS	87
3.10	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	87
3.11	METHODS FOR REDUCING TOXIC EFFECTS	88
3.11.1	Reducing Peak Absorption Following Exposure	88
3.11.2	Reducing Body Burden	88
3.11.3	Interfering with the Mechanism of Action for Toxic Effects	89
3.12	ADEQUACY OF THE DATABASE	89
3.12.1	Existing Information on Health Effects of Americium	90
3.12.2	Identification of Data Needs	90
3.12.3	Ongoing Studies	97
4.	CHEMICAL, PHYSICAL, AND RADIOLOGICAL INFORMATION	99
4.1	CHEMICAL IDENTITY	99
4.2	PHYSICAL, CHEMICAL, AND RADIOLOGICAL PROPERTIES	99
5.	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	105
5.1	PRODUCTION	105
5.2	IMPORT/EXPORT	106
5.3	USE	106
5.4	DISPOSAL	106
6.	POTENTIAL FOR HUMAN EXPOSURE	109
6.1	OVERVIEW	109
6.2	RELEASES TO THE ENVIRONMENT	113
6.2.1	Air	113
6.2.2	Water	115
6.2.3	Soil	116
6.3	ENVIRONMENTAL FATE	118
6.3.1	Transport and Partitioning	118
6.3.2	Transformation and Degradation	135
6.3.2.1	Air	135
6.3.2.2	Water	135
6.3.2.3	Sediment and Soil	135
6.4	LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	136
6.4.1	Air	136
6.4.2	Water	138
6.4.3	Soil	140
6.4.4	Other Environmental Media	143
6.5	GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	155
6.6	EXPOSURES OF CHILDREN	160
6.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	161

6.8	ADEQUACY OF THE DATABASE	162
6.8.1	Identification of Data Needs	162
6.8.2	Ongoing Studies	165
7.	ANALYTICAL METHODS	167
7.1	BIOLOGICAL MATERIALS	167
7.1.1	Internal Americium Measurements	167
7.1.2	External Radiation Measurements	172
7.2	ENVIRONMENTAL SAMPLES	173
7.2.1	Field Measurements of Americium	173
7.2.2	Laboratory Analysis of Environmental Samples	175
7.3	ADEQUACY OF THE DATABASE	182
7.3.1	Identification of Data Needs	183
7.3.2	Ongoing Studies	183
8.	REGULATIONS AND ADVISORIES	185
9.	REFERENCES	193
10.	GLOSSARY	235

APPENDICES

A.	ATSDR MINIMAL RISK LEVEL AND WORKSHEETS	A-1
B.	USER'S GUIDE	B-1
C.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS	C-1
D.	OVERVIEW OF BASIC RADIATION PHYSICS, CHEMISTRY AND BIOLOGY	D-1

LIST OF FIGURES

3-1.	Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance	53
3-2.	Respiratory Tract Compartments in Which Particles May be Deposited	55
3-3.	Reaction of Gases or Vapors at Various Levels of the Gas-Blood Interface	60
3-4.	Compartment Model to Represent Time-Dependent Particle Transport in the Respiratory Tract	61
3-5.	The Human Respiratory Tract Model: Absorption into Blood	64
3-6.	ICRP (1989) Model of Americium Biokinetics	66
3-7.	Leggett (1992) Model of Americium Biokinetics	69
3-8.	Leggett (1992) Model of Deposition and Retention of Americium in the Human Respiratory Tract	70
3-9.	Mewhinney and Griffith (1983) Model of Deposition and Retention of Americium in the Human Respiratory Tract	74
3-10.	Durbin and Schmidt (1985) Model of Distribution and Excretion of Absorbed Americium in the Human	76
3-11.	Existing Information on Health Effects of Americium	91
6-1.	Frequency of NPL Sites with Americium Contamination	110

LIST OF TABLES

3-1.	Retention and Absorption Estimates in Animals Exposed to Americium Compounds by Inhalation	31
3-2.	Absorption Estimates in Animals Exposed to Americium Compounds by Ingestion	37
3-3.	Tissue Americium Levels from Human Autopsies	42
3-4.	Reference Respiratory Values for a General Caucasian Population at Different Levels of Activity	57
3-5.	Reference Values of Parameters for the Compartment Model to Represent Time-dependent Particle Transport from the Human Respiratory Tract	58
4-1.	Principal Americium Isotopes	100
4-2.	Physical and Chemical Properties of Americium and Selected Americium Compounds ...	102
4-3.	Properties of Some Americium Ions	104
6-1.	Concentrations of Americium 241 in Soil and Sediment	120
6-2.	Bioconcentration Factors for ²⁴¹ Am	132
6-3.	Concentrations of ²⁴¹ Am in Water	139
6-4.	Average Concentrations of ²⁴¹ Am in Food	144
6-5.	Concentrations of ²⁴¹ Am in Fauna	148
6-6.	Estimated Effective ²⁴¹ Am Dose from Food Raised on Land Impacted by Tidal Estuaries along the Irish Sea	157
6-7.	Ongoing Studies on Environmental Effects of Americium	166
7-1.	Analytical Methods for Determining Americium in Biological Samples	168
7-2.	Analytical Methods for Determining Americium in Environmental Samples	176
8-1.	Regulations and Guidelines Applicable to Americium	186